ArticleApplied and environmental microbiology2006
Overproduction of wild-type and bioengineered derivatives of the lantibiotic lacticin 3147.
Article in Applied and environmental microbiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 41 citations in OpenAlex.
- Synergistic and off-target effects of bacteriocins in a simplified human intestinal microbiome: implications forGut microbes · 2025Article
- Incorporation of Non-Canonical Amino Acids into Antimicrobial Peptides: Advances, Challenges, and Perspectives.Applied and environmental microbiology · 2022Review
- A Cell-Free Platform Based on Nisin Biosynthesis for Discovering Novel Lanthipeptides and Guiding their Overproduction In Vivo.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Identification and characterisation of capidermicin, a novel bacteriocin produced by Staphylococcus capitis.PloS one · 2019Article
- The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria.BMC microbiology · 2013Article
- Comparison of the Potency of the Lipid II Targeting Antimicrobials Nisin, Lacticin 3147 and Vancomycin Against Gram-Positive Bacteria.Probiotics and antimicrobial proteins · 2012Article
- Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V.Microbial biotechnology · 2010Article
- Influence of Ca(2+) ions on the activity of lantibiotics containing a mersacidin-like lipid II binding motif.Applied and environmental microbiology · 2009Article
- Continuous nisin production with bioengineered Lactococcus lactis strains.Journal of industrial microbiology & biotechnology · 2009Article
- Influence of growth conditions on the nisin production of bioengineered Lactococcus lactis strains.Journal of industrial microbiology & biotechnology · 2009Article
- Mechanistic dissection of the enzyme complexes involved in biosynthesis of lacticin 3147 and nisin.Applied and environmental microbiology · 2008Article
- Insertional mutagenesis to generate lantibiotic resistance in Lactococcus lactis.Applied and environmental microbiology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lacticin 3147 is a broad-spectrum two-peptide lantibiotic whose genetic determinants are located on two divergent operons on the lactococcal plasmid pMRC01. Here we introduce each of 14 subclones, containing different combinations of lacticin 3147 genes, into MG1363 (pMRC01) and determine that a number of them can facilitate overproduction of the lantibiotic. Based on these studies it is apparent that while the provision of additional copies of genes encoding the biosynthetic/production machinery and the regulator LtnR is a requirement for high-level overproduction, the presence of additional copies of the structural genes (i.e., ltnA1A2) is not.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.